Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DR-2021a · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | EXPERIMENTAL | - |
| 6 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DR-2021a | DRUG | 1 capsule daily for 10 days |
| DR-2021b | DRUG | 1 capsule daily for 10 days |
| DR-2021c | DRUG | 1 capsule daily for 10 days |
| DR-2021d | DRUG | 1 capsule daily for 10 days |
| DR-2021e | DRUG | 1 capsule daily for 10 days |
| Placebo | OTHER | 1 matching placebo capsule for 10 days |
Inclusion Criteria: * Not pregnant * Secondary amenorrhea or oligomenorrhea of at least 50 days duration * Not currently on any hormonal medication * Not at risk of pregnancy or willing to use a non-hormonal method of birth control during the study (ie, condom) Exclusion Criteria: * Use an inject...
DR-2021a is an investigational small molecule being developed for the treatment of amenorrhea, specifically evaluated in women with secondary amenorrhea. It is in Phase 2 clinical development and is not yet approved by regulatory authorities.
DR-2021a is being developed by Teva Pharmaceutical Industries Limited, a company publicly traded under the ticker symbol TEVA. The drug is currently in Phase 2 clinical trials for amenorrhea.
DR-2021a is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. One Phase 2 trial has been completed for this asset.
DR-2021a has one completed Phase 2 clinical trial, identified as NCT00196391, titled 'A Trial to Evaluate DR-2021 in Women With Secondary Amenorrhea'. This randomized, double-blind, placebo-controlled study enrolled 180 female participants in the United States.
DR-2021a is the drug name used in the clinical trial record NCT00196391. The trial evaluates DR-2021 in women with secondary amenorrhea, and DR-2021a appears to be the same compound referenced in this study.